کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10909736 | 1087936 | 2005 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience](/preview/png/10909736.png)
چکیده انگلیسی
High dose intermittent ARA-C (2Â ÃÂ 3Â g/m2 i.v., days 1, 3, 5)Â =Â HiDAC was introduced as consolidation in AML by the CALGB-group in 1994. We treated 44 de novo AML patients in CR with up to four cycles of HiDAC (four cycles: 56.8%; three cycles: 22.7%; two cycles: 6.8%; one cycle: 13.7%). Median duration of aplasia (ANCÂ <Â 0.5Â ÃÂ 109/l) was 12 days. Neutropenic fever occurred in 38.6% of the patients during the first, 52.6% during the second, 45.7% during the third, and in 40% during the fourth cycle. Non-hematologic toxicity was tolerable. The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 29, Issue 6, June 2005, Pages 609-615
Journal: Leukemia Research - Volume 29, Issue 6, June 2005, Pages 609-615
نویسندگان
Alexandra Böhm, Maria Piribauer, Friedrich Wimazal, Klaus Geissler, Heinz Gisslinger, Paul Knöbl, Ulrich Jäger, Christa Fonatsch, Paul A. Kyrle, Peter Valent, Klaus Lechner, Wolfgang R. Sperr,